株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

接触性皮膚炎:パイプライン製品の分析

Contact Dermatitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 293884
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
接触性皮膚炎:パイプライン製品の分析 Contact Dermatitis - Pipeline Review, H2 2016
出版日: 2016年09月30日 ページ情報: 英文 69 Pages
概要

接触性皮膚炎とは、何かが皮膚に触れることによって炎症やアレルギー反応が起こる皮膚炎の一種です。症状は赤い発疹や丘疹、紅斑などが現れます。治療には経口副腎皮質ステロイドや抗ヒスタミン剤を用いて激しいかゆみを和らげます。

当レポートでは、接触性皮膚炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどを提供して、概略以下の構成でお届けいたします。

目次

イントロダクション

接触性皮膚炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Anacor Pharmaceuticals, Inc.
  • Celsus Therapeutics Plc
  • Marinomed Biotechnologie GmbH
  • R-Tech Ueno, Ltd.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子の種類別

薬剤のプロファイル

  • AAT-008
  • AN-3485
  • grapiprant
  • HPT-721
  • MAM-06301
  • MRX-6
  • pertussis strain BPZE1 vaccine
  • RTU-1096

パイプライン製品の最新動向

休眠中のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8519IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H2 2016, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 9 respectively for Contact Dermatitis.

Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Contact Dermatitis Overview
  • Therapeutics Development
    • Pipeline Products for Contact Dermatitis - Overview
  • Contact Dermatitis - Therapeutics under Development by Companies
  • Contact Dermatitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Contact Dermatitis - Products under Development by Companies
  • Contact Dermatitis - Companies Involved in Therapeutics Development
    • Aldeyra Therapeutics Inc
    • Anacor Pharmaceuticals, Inc.
    • AskAt Inc.
    • Brickell Biotech, Inc.
    • Dr. August Wolff GmbH & Co. KG Arzneimittle
    • Edesa Biotech Inc
    • Hapten Sciences, Inc.
    • ILiAD Biotechnologies, LLC
    • LegoChem Biosciences, Inc
    • Marinomed Biotechnologie GmbH
    • Novartis AG
    • Signum Dermalogix, Inc
    • Sucampo Pharmaceuticals, Inc.
  • Contact Dermatitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AAT-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-3485 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBI-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beta-escin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPT-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-030110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RTU-1096 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • secukinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SIG-1322 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WOL-071007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Contact Dermatitis - Dormant Projects
  • Contact Dermatitis - Discontinued Products
  • Contact Dermatitis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Contact Dermatitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Contact Dermatitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016
  • Contact Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
  • Contact Dermatitis - Pipeline by AskAt Inc., H2 2016
  • Contact Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2016
  • Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016
  • Contact Dermatitis - Pipeline by Edesa Biotech Inc, H2 2016
  • Contact Dermatitis - Pipeline by Hapten Sciences, Inc., H2 2016
  • Contact Dermatitis - Pipeline by ILiAD Biotechnologies, LLC, H2 2016
  • Contact Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2016
  • Contact Dermatitis - Pipeline by Novartis AG, H2 2016
  • Contact Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2016
  • Contact Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Contact Dermatitis - Dormant Projects, H2 2016
  • Contact Dermatitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Contact Dermatitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top